Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver diseaseXinrong Zhang, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong et al.|Hepatology|2021Cited by 91
Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver diseaseXinrong Zhang, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong et al.|Hepatology|2022Cited by 54
Non-invasive tests of non-alcoholic fatty liver diseaseGuanlin Li, Vincent Wai‐Sun Wong, Xinrong Zhang et al.|Chinese Medical Journal|2022Cited by 51
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver diseaseHuapeng Lin, Vincent Wai‐Sun Wong, Lilian Yan Liang et al.|Hepatology|2022Cited by 50
Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trialXinrong Zhang, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip et al.|Gut|2023Cited by 47